Revolutionise cardiac testing in your market!!

The Cardiac Array uses Biochip Array Technology to simultaneously & quantitatively assess four acute cardiac biomarkers from a single patient sample.

It offers a comprehensive biochemical profile of patients presenting to hospital with chest pain and suspected heart attack.

Combined with Evidence MultiStat, highly precise results are available within 30 minutes for up to two patient samples.

Cardiac Markers

The Chest Pain Challenge

Cardiovascular disease (CVD) is responsible for over 18.5 million deaths each year and costs the global economy over 500 billion euro. One of most common forms of CVD is chest pain and this leads to an estimated 5% of all visits to the Emergency Department (ED) and around 25% of all ED admissions 16.

Major heart attacks are relatively straight forward to diagnose. However, these only represent a small amount of the total patients arriving at hospital with chest pain. In fact, research has found that at least 70% of all patients attending hospital with chest pain do not even have a cardiac related condition and many of these are actually admitted to a highly expensive level of care (e.g. Coronary Care Unit)17.

This is largely because current methods of assessing chest pain and heart attacks are not entirely reliable. Although ECGs are useful for detecting major heart attacks (STEMI), they are not sensitive for diagnosing less obvious cases. This is where biomarkers offer a major advantage.

Many international guidelines (American College of Cardiology/European Society of Cardiology) recommend that Troponin should be used as the main biomarker for diagnosing heart attacks. CK-MB is also widely used. However, the problem with these biomarkers is that they do not become elevated until 5-6 hours after symptom onset.

This delay means that many low risk patients are unnecessarily kept in hospital for 12-24 hours or longer, when they could have been discharged much earlier.  Earlier discharge of these patients could potential save a huge amount of expense for the hospital.

How can the Cardiac Array help?

The Cardiac Array uses a combination of traditional cardiac biomarkers (Troponin I, CK-MB and Myoglobin) with the novel early rise marker, H-FABP.

H-FABP has been repeatedly shown to offer huge potential benefits in two main areas:

Diagnostic Ability (initial diagnosis or discharge)

• Has been shown to rise as early as 30 minutes after a cardiac event - therefore very useful as an early indicator of myocardial damage. Can enable medical staff to identify heart attacks earlier and risk stratify these patients (rather than waiting for a 12 hour Troponin).
• When combined with Troponin, CK-MB and Myoglobin, it offers a 98% accurate rule out test for heart attacks. Also, the combination has been shown to be 20% more sensitive than a single Troponin test.
• Ability to detect high risk patients otherwise missed if only relying on Troponin and/or CK-MB
  

Prognostic Ability (long term outcome)

• Strongly predictive of mortality after heart attack - it improves the prediction of repeat heart attacks or mortality within 18 months, regardless of whether the patient was Troponin positive or negative
• A negative result for H-FABP & Troponin after 12 hours, offers 0% mortality over the next six months. This offers doctors great confidence to discharge patients.
• H-FABP still has excellent prognostic ability, even when a new high sensitivity Troponin assay is used. If a patient is Troponin negative with such an assay, a positive H-FABP identifies very high risk patients.
• Randox H-FABP assay has the same sensitivity & specificity as high sensitivity Troponin